News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Francesco Massari: Another Important Experience by ARON Project on First-Line Treatment Options for mRCC patients
Francesco Massari/X
May 30, 2025, 13:07

Francesco Massari: Another Important Experience by ARON Project on First-Line Treatment Options for mRCC patients

Francesco Massari, Medical Oncologist focused on Genitourinary Cancer at The University Hospital of Bologna IRCCS, shared a post on X:

“Pembro/Axi vs. Nivo/Cabo
as first-line therapy in mRCC patients.
Out now another important experience by ARON Project.”

ARON Project

Title: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Authors: Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

Read Full Article.

Francesco Massari: Another Important Experience by ARON Project on First-Line Treatment Options for mRCC patients

More posts featuring Renal Cell Carcinoma on OncoDaily.

Alfonso Gómez de Liaño Alvaro Pinto Anca Zgura Aristotelis Bamias ARON project Camillo Porta cancer Caterina Gianni Dipen Bhuva Emmanuel Seront Enrique Grande Francesco Massari Giandomenico Roviello Jakub Kucharz Javier Molina Cerrillo Jawaher Ansari Jindrich Kopecky Kaisa Sunela Linda Cerbone Maria Giuseppa Vitale Maria T Bourlon Martin Pichler Martina Catalano Matteo Santoni Nuno Vau OncoDaily Oncology Ondřej Fiala Orazio Caffo Pasquale Rescigno Ravindran Kanesvaran Ray Manneh Kopp Renate Pichler Sebastiano Buti Thomas Büttner Tomas Buchler Ugo de Giorgi Umberto Basso Zin W. Myint Zsófia Küronya
Special Coverage
Blog
Jun 23, 2025, 07:10
Giannis Mountzios Reflects on DeLLphi-304 Trial Impact on Recurrent SCLC
Dialogues
Jun 23, 2025, 07:07
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
Blog
Jun 23, 2025, 07:01
Ibrahim Halil Sahin: I received the David Roodman Excellence in Mentoring Award
Insight
Jun 23, 2025, 06:59
Jason Westin: Mosun-Pola Is Superior to Chemotherapy for Patients with Aggressive Lymphoma
Blog
Jun 23, 2025, 06:51
Sakditad Saowapa: Excited to Share Our Work at ISTH 2025
Blog
Jun 23, 2025, 06:46
Charles Roberts Highlights Father–Son Scientists Advancing Research at St. Jude
Science
Jun 23, 2025, 06:44
The First AI-Powered Platinum Drug Candidate That Defeats Cisplatin Resistance - The Babak Lab
Blog
Jun 23, 2025, 06:38
Shivani Modi: Elderly Woman’s Battle with Post-Transfusion Purpura and Alveolar Haemorrhage
Blog
Jun 23, 2025, 06:04
Vivek Subbiah: Reflecting on a Successful ASCO and the Bright Future of Cancer Treatment
Insight
Jun 23, 2025, 05:54
Marc Oliva Highlights Landmark Study for LA-HNSCC Published in NEJM
Blog
Jun 23, 2025, 05:42
Emad Shash: Calling All Oncology and Allied-Health Professionals
Insight
Jun 23, 2025, 05:22
Emmanuel Antonarakis Highlights HOXB13 Mutation Linked to Prostate Cancer Risk and Hormonal Therapy Sensitivity